Moderna Finds 'Robust Antibody Response' in Omicron-Specific Booster

Damian McNamara, MA

June 08, 2022

Editor's note: Find the latest COVID-19 news and guidance in Medscape's Coronavirus Resource Center.

Take that, Omicron. Results of a trial looking at a combination COVID-19 vaccine booster reveals a "robust antibody response" against the Omicron variant, vaccine manufacturer Moderna announced Wednesday.

The neutralizing antibody response was eight times greater at 1 month following a 50-mcg dose with the booster containing both the original mRNA-1273 vaccine and a new vaccine in development that specifically targets the Omicron variant.

The bivalent vaccine, mRNA-1273.214, was compared to a 50-mcg dose of the original vaccine alone in 473 seronegative participants in the Phase 2/3 trial.

These results offer promise of greater protection against Omicron following earlier reports that showed that existing COVID-19 vaccines were not as effective against the Omicron variant.

Safety and tolerability of the new vaccine was consistent with a prior booster dose of the original vaccine, the company reported.

Moderna also has a bivalent vaccine booster in development that includes the original vaccine and a vaccine specific to the Beta variant of SARS-CoV-2, the virus that causes COVID-19.

Moderna plans to file this new data with the FDA as part of its application requesting authorization.

"We anticipate more durable protection against variants of concern with mRNA-1273.214, making it our lead candidate for a Fall 2022 booster," Stephane Bancel, chief executive officer at Moderna, said in a company news release. "We are submitting our preliminary data and analysis to regulators with the hope that the Omicron-containing bivalent booster will be available in the late summer."


Moderna news release, June 8, 2022.


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.